Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters containing preclinical data relating to the mitotic kinesin centromere-associated protein E (CENP-E) and an inhibitor of CENP-E, GSK-923295, were presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer in San Francisco. GSK-923295 is the subject of an ongoing first-time-in-humans Phase I clinical trial being conducted by GlaxoSmithKline (GSK) which is designed to evaluate the safety, tolerability and pharmacokinetics of GSK-923295 in patients with solid tumors.
